GlassScriptPhysician profile
Muhammad I Ali
NPI 1861659351
$20,580.34
in general payments reported to CMS, 2019-2025
51 companies · $2,856 in 2025
The $2,856 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,640 · 2020: $2,003 · 2021: $2,573 · 2022: $2,856 · 2023: $3,546 · 2024: $5,106 · 2025: $2,856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,936 · Education: $2,065 · Travel and Lodging: $506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,936.04 |
| Education | $2,065.47 |
| Travel and Lodging | $506.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,287.98 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $3,026.33 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Intuitive Surgical, INC. | $2,590.65 | 2023-2025 | Da Vinci Surgical System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,110.27 | 2019-2024 | Spiriva Respimat, Stiolto Respimat |
| Grifols USA, LLC | $906.27 | 2019-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $866.89 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $841.56 | 2019-2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $736.41 | 2022-2025 | Acthar, Terlivaz |
| Actelion Pharmaceuticals US, INC. | $730.09 | 2020-2025 | Uptravi, Opsumit, Opsynvi |
| Janssen Pharmaceuticals, INC | $683.78 | 2019-2022 | |
| Electromed, INC. | $606.38 | 2019-2025 | Smartvest |
| Amgen INC. | $546.79 | 2021-2025 | Tezspire |
| Merck Sharp & Dohme LLC | $454.55 | 2019-2025 | Winrevair |
| Pulmonx Corporation | $371.84 | 2020-2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Insmed, INC. | $341.82 | 2020-2025 | Arikayce |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.